EyePoint Investors Face 66% Loss Following Failed Phase 3 Trial

The trouble began on August 17, 2026, when EyePoint released topline data from its LUGANO study. The trial, intended to test the efficacy of the vorolanib intravitreal insert for wet age-related macular degeneration, failed to demonstrate the necessary visual acuity improvements when compared to aflibercept. This shortfall in the full dataset sent the company’s stock into a sharp decline, wiping out significant value for shareholders.

Kessler Topaz Meltzer & Check, LLP, a firm specializing in securities-fraud class actions, is now evaluating the circumstances surrounding these disclosures. They are inviting investors who incurred financial losses during this period to come forward to discuss potential legal remedies. The firm, which maintains offices in Pennsylvania and California, focuses on representing both individual and institutional investors in high-stakes litigation.